12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Company News  |  Deals

Proacta, Yakult deal

The partners expanded a February deal to give Yakult Honsha exclusive rights to cancer candidate PR610 in Japan. The partners will complete preclinical testing and Phase I trials of the compound in the U.S. after which Yakult can exercise the option to further...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >